10-Q: Earth Science Tech Reports Q2 2026 Growth

Earth Science Tech, Inc. announced its Q2 2026 results, showcasing a 3% revenue increase and a significant rise in net income, driven by operational efficiencies and strategic investments.

Summary

• Earth Science Tech, Inc. reported for the quarter ended June 30, 2026, with total assets increasing by 16% to $10,374,013 from $8,969,337.
• Total liabilities rose by 56% to $3,009,743, primarily due to increased vendor pricing strategies and new operating lease liabilities.
• Total equity grew by 5% to $7,364,270, despite $392,191 being used for share repurchases.
• Net income for the period was $715,697, a 57% increase from $456,714 in the prior year's quarter.
• Revenue for the quarter increased by 3% to $9,025,779 from $8,760,190 in the same period last year.
• Cost of goods sold also increased by 3% to $2,750,510, maintaining a stable gross margin of approximately 70%.
• Net cash provided by operating activities significantly increased to $707,131 from $339,376 in the prior year.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive filing, reflecting revenue growth and improved net income, alongside strategic initiatives like share repurchases and operational efficiencies, though increased liabilities and marketing spend warrant attention.

Positives

• Revenue increased by 3% to $9,025,779 for the three months ended June 30, 2026, compared to $8,760,190 in the prior year.
• Gross profit increased by $184,494, or 3%, to $6,275,269, with gross margin remaining stable at approximately 70%.
• Net income available to common stockholders increased to $724,192 from $465,039 in the prior year.
• Net income before taxes saw a substantial increase of 110% to $958,352 from $456,714.
• Net cash provided by operating activities more than doubled to $707,131 from $339,376.
• The company repurchased and retired 3,733,726 shares of its common stock for $392,191, reducing the number of outstanding shares.
• Salaries expense decreased by 15% to $3,217,201, attributed to voluntary compensation adjustments by the CEO and COO.
• Total assets increased by 16% to $10,374,013, indicating growth and investment in expansion initiatives.

Negatives

• Total liabilities increased by 56% to $3,009,743, primarily due to leveraging purchasing capacity for vendor pricing and new operating lease liabilities.
• Advertising and marketing expenses increased by 34% to $850,004, reflecting significant ongoing strategic marketing initiatives.
• Legal and professional fees increased by 80% to $131,912, largely due to higher audit-related fees from a transition of audit firms.
• Interest expense increased by 279% to $16,197, attributed to the use of leverage for investment strategies.
• Cash and cash equivalents decreased by $165,679 to $631,118 from $796,797 at the beginning of the period.
• The company has a substantial accumulated deficit of $23,384,007 as of June 30, 2026.

Risks

• The company is a smaller reporting company and is not required to provide detailed risk factor disclosures under Item 1A.
• Net operating loss carry forwards are subject to limitations under Internal Revenue Code Section 382 after certain ownership changes, and management has not determined the exact amount available.
• The Series B Preferred Stock grants the CEO voting control, which could lead to decisions not aligned with all shareholders if the CEO ceases to serve as an officer or director.
• The company's strategy involves leveraging purchasing capacity, which increases liabilities and could pose risks if vendor pricing or lease terms become unfavorable.

Future Outlook

The company's principal operating strategy is to build a vertically integrated healthcare platform. Management believes its current asset growth positions it to continue pursuing expansion initiatives and creating long-term shareholder value. The company is also evaluating options for potential reorganization of its reporting segments in future periods.

Management Comments

• Management believes the growth in total assets positions the Company to continue pursuing its expansion initiatives and reflects its ongoing commitment to creating long-term shareholder value.
• The increase in total liabilities was primarily due to the Company's strategy of leveraging its purchasing capacity to obtain more favorable vendor pricing and support improved gross margins.
• The increase in total equity was net of $392,191 used to repurchase and cancel shares of its common stock during the quarter, which reduced the number of shares outstanding, potentially increasing each remaining shareholder's proportionate ownership and earnings per share.
• Salaries expense decrease was primarily attributable to voluntary modifications to the compensation arrangements of the Companys Chief Executive Officer (CEO) and Chief Operating Officer (COO), who agreed to rescind portions of their previously approved compensation and accept interim compensation adjustments.

Industry Context

StockSavvy.ai notes that Earth Science Tech operates in the health and wellness sector, aiming for a vertically integrated healthcare platform. This aligns with broader industry trends towards consolidation and integrated care models, combining pharmacy, telemedicine, and direct-to-patient fulfillment. The company's expansion of state licensure supports this strategy in a competitive market.

Comparison to Industry Standards

• The company's gross margin of approximately 70% is strong, particularly for a business involved in pharmaceutical products and medical consultations, suggesting efficient cost management in its core operations.
• The significant increase in advertising and marketing spend (34%) reflects a competitive landscape where customer acquisition and brand visibility are crucial, a common challenge for companies in the health tech and wellness sectors.
• The increase in interest expense due to leverage for investment strategies is a common practice in the industry to potentially enhance returns, but it also introduces financial risk.
• The company's focus on non-dilutive financing and share repurchases, coupled with high insider ownership (48%), is a governance strategy aimed at shareholder alignment, which is viewed positively by many institutional investors.

Corporate Governance

Legal Proceedings

• As of June 30, 2026, there were no pending or threatened legal actions that, in management's opinion, are expected to have a material adverse effect on the Company's financial position, results of operations, or cash flows.

Related Party Transactions

• Compensation paid to two officers for services provided to their solely owned LLCs (Point96 Consulting, LLC and Tabraue Consulting, LLC).
• Lease of office space under a short-term operating lease from Zoolzy, LLC, an entity controlled by an officer, under a sub-lease agreement. Lease payments of $21,680 were made in Q2 2026.

Stakeholder Impact

• Shareholders: Benefit from share repurchases potentially increasing EPS and proportionate ownership. CEO's voting control via preferred stock could influence strategic decisions.
• Employees: Impacted by salary expense reductions due to executive compensation adjustments.
• Vendors/Suppliers: May benefit from increased purchasing capacity and improved vendor pricing strategies, though this also increases company liabilities.
• Creditors: Company remains free of long-term debt, indicating a low risk profile for creditors regarding long-term obligations.

Next Steps

• Continue to build a vertically integrated healthcare platform.
• Expand state licensure for pharmacy and telehealth services.
• Manage share repurchase program.
• Evaluate options for potential reorganization of reporting segments.

Key Dates

Recommendation

The company shows positive revenue and net income growth, alongside strategic share repurchases and operational efficiencies. However, the significant increase in liabilities, rising interest expenses, and substantial accumulated deficit warrant a cautious approach. The concentrated voting control by the CEO also presents a governance consideration. Therefore, a 'hold' recommendation is appropriate pending further evidence of sustained profitability and debt management.

Keywords

pharmacy operations, telemedicine, compounding pharmacy, healthcare platform, asset management, share repurchase, financial results, revenue growth